NFE2L2, nuclear factor, erythroid 2 like 2, 4780

N. diseases: 823; N. variants: 34
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
0.600 GeneticVariation disease BEFREE Recently, somatic mutations that activate NFE2L2, including mutations in <i>NFE2L2, KEAP1</i>, or <i>CUL3</i>, have been found to be associated with poor outcomes in patients with non-small cell lung cancer (NSCLC). 31548347 2020
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
0.600 GeneticVariation disease BEFREE Erastin and APAP promoted NSCLC cell death by regulating nucleus translocation of nuclear factor erythroid 2-related factor 2 (Nrf2); and the ferroptosis induced by erastin and APAP was abrogated by bardoxolone methyl (BM) with less generation of reactive oxygen species and malondialdehyde. 31541463 2020
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
0.600 GeneticVariation disease BEFREE To clarify metabolic features of NRF2-activated lung cancers, we conducted targeted metabolomic (T-Met) and global metabolomic (G-Met) analyses of non-small-cell lung cancer (NSCLC) cell lines in combination with exome and transcriptome analyses. 31828882 2020
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 Biomarker disease BEFREE Several Nrf2 activators are at various stages of clinical development and are being tested in clinical trials for chronic kidney disease (CKD) including diabetic kidney disease, Alport syndrome, autosomal dominant polycystic kidney disease and focal segmental glomerulosclerosis. 31592832 2020
CUI: C0034069
Disease: Pulmonary Fibrosis
Pulmonary Fibrosis
0.600 Biomarker disease BEFREE The nuclear factor E2-related factor 2 (Nrf2) plays an important regulatory role in the antioxidant therapy of PQ-induced pulmonary fibrosis. 31301076 2020
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
0.600 AlteredExpression disease BEFREE In non-small cell lung cancer (NSCLC) cells and xenografts, MKP-1 knockdown triggered the down-regulation of the metabolic enzymes and cytoprotective proteins, which are the target genes of Nrf2. 31811110 2019
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
0.600 Biomarker disease BEFREE SIGNIFICANCE: This study identifies pathways activated by Nrf2 that are important for the proliferation and tumorigenicity of KEAP1-mutant non-small cell lung cancer. 31416841 2019
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
0.600 AlteredExpression disease BEFREE Nrf2 expression was not correlated with prognosis in two types of NSCLC. 30868898 2019
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
0.600 GeneticVariation disease BEFREE Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer. 31319993 2019
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
0.600 Biomarker disease BEFREE Taken together, our results indicate that the Nestin-Keap1-Nrf2 axis regulates cellular redox homeostasis and confers oxidative stress resistance in NSCLC. 31695040 2019
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
0.600 AlteredExpression disease BEFREE Finally, we report that NRF2 protein expression in a NSCLC cohort exceeds the typical incidence of combined NRF2, KEAP1, and CUL3 mutations, and that NRF2 expression in this cohort is correlated with PIDD levels. 31455821 2019
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
0.600 Biomarker disease BEFREE This study demonstrates that the NRF2 pathway may serve as a therapeutic target in NSCLC, and ginseng compounds may be effective for the treatment of this disease. 31415285 2019
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
0.600 GeneticVariation disease BEFREE Molecular characterization studies revealed recurrent kelch like ECH associated protein 1 gene (KEAP1)/nuclear factor, erythroid 2 like 2 gene (NFE2L2) alterations in NSCLC. 31323387 2019
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
0.600 AlteredExpression disease BEFREE Using multiple isogenic non-small cell lung cancer (NSCLC) cell lines, we observed a reduction of Nrf2 protein and activity in a prometastatic mesenchymal cell state and increased reactive oxygen species. 31581742 2019
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 Biomarker disease BEFREE Our present study suggested that Blnc1 can affect inflammation, oxidative stress and renal fibrosis by Nrf2/HO-1 and NF-κB pathways in DN. 31632538 2019
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 AlteredExpression disease BEFREE Sitagliptin may induce HO-1 expression via activation of PI3K and Nrf2 in rats with diabetic nephropathy; HO-1 can improve the oxidative stress of diabetic nephropathy, eventually protect from diabetic nephropathy. 30128961 2019
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 Biomarker disease BEFREE Further exploration indicate that Nrf2 plays pivotal role in AB-38b's attenuation of DN progression through inhibiting NLRP3 inflammasome activation. 31768838 2019
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 AlteredExpression disease BEFREE The purpose of this study is to better understand the Nrf2-ARE antioxidant activity of MIC-1 and its potential in diabetic nephropathy. 30783799 2019
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 Biomarker disease BEFREE Moreover, our findings provided a fuller understanding of the regulatory role of NF-κB and Nrf2 in DN, indicating that they could be important therapeutic targets. 30477745 2019
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 Biomarker disease BEFREE This finding implicates BRD4/Nrf2/ARE signaling in the pathogenesis of diabetic nephropathy. 31325480 2019
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 GeneticVariation disease BEFREE Deletion of the Nrf2 gene completely abrogated the efficacies of SRT2104 and PFT-α in elevating antioxidants and ameliorating DN, despite their abilities to activate SIRT1 and inhibit P53 in the Nrf2 KO mice. 30959066 2019
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 AlteredExpression disease BEFREE Multiple metabolic pathways of DKD have been evaluated with varying success; including mitochondrial function, reactive oxygen species, NADPH oxidase (NOX), transcription factors (NF-B and Nrf2), advanced glycation, protein kinase C (PKC), aldose reductase, JAK-STAT, autophagy, apoptosis-signaling kinase 1 (ASK1), fibrosis and epigenetics. 31154867 2019
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 Biomarker disease BEFREE Bergenin can inhibit glucose-induced ECM production in glomerular mesangial cells through the down-regulation of oxidative stress via the mTOR/β-TrcP/Nrf2 pathway, and it might be a candidate drug for the prevention and treatment of DN. 31494242 2019
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 AlteredExpression disease BEFREE Notoginsenoside R1 Protects db/db Mice against Diabetic Nephropathy via Upregulation of Nrf2-Mediated HO-1 Expression. 30634720 2019
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 Biomarker disease BEFREE The aim of this study was to evaluate the renoprotective effects of hesperetin against DN in rats, and to investigate mechanisms from the aspect of Nrf2/ARE/Glo-1 pathway. 30841430 2019